Introduction

Several changes in the immune system occur during pregnancy (1), of which prominent ones are the localized protective mechanisms of the placenta and systemic immune responses (2,3). Immune responses are categorized as cell mediated reactions by T helper1 (Th1) and humoral responses by T helper2 (Th2). Since Th1 cytokines can have adverse effects on the fetus, a shift in T-cell physiology from Th1 to Th2 immune responses occurs in pregnant women (4,5). Alterations in cellular immunity have also been reported during pregnancy; although during the first trimester, helper/suppressor ratio (CD4/CD8) is increased, it declines in the two following trimesters (6).

Specific immune responses mentioned above are slowly lost during the postpartum period. Prior to return to the pre-pregnancy state, there is a “period of exacerbation” of immune reactivity, 3 to 12 months following delivery (1,7); this over-reactivity is accompanied by beginning, relapse or worsening of autoimmune thyroid disorders. Although all disorders of thyroid may occur within 12 months of birth, two major presentations of thyroid dysfunction in this period are postpartum thyroiditis (PPT) and Graves' disease (GD).

The aim of this article is to review causes, predictors, clinical presentations, diagnosis and management of PPT and postpartum thyrotoxicosis.

PPT

Postpartum thyroid dysfunction (PPTD) includes a category of autoimmune disorders, distinguished by postpartum occurrence of transient or permanent thyroid dysfunction. PPT is an autoimmune disease and worldwide epidemiological studies have documented a wide range of PPT prevalence, 1.1% to 11.4% (8-15). Differences in the rate of PPT are probably related to variations in ethnicity, geographical locations, and methods or numbers of follow-up visits in the first year post-delivery (16-18). The mean prevalence is approximately 7% (19). PPT is more prevalent in women with other autoimmune disorders and particularly in women with type 1 diabetes in whom its prevalence may
reach as high as 18–25% (20-22).

**Predictors of PPT**

This disease is related to immunologic disturbances that occur in pregnancy and postpartum period. There is a distinct association of PPT with elevated maternal serum thyroid peroxidase antibodies (TPOAb) (23). It is reported that half of TPOAb positive women will eventually be affected by PPT (1,24) and a large number of these patients will develop permanent hypothyroidism. In one study, permanent hypothyroidism occurred in 22 out of 48 (46%) of TPOAb positive with PPT and 1 out of 70 (1.4%) TPOAb negative women without PPT (12). In the largest cohort of women with PPT, 63% of 148 women became permanently hypothyroid 1–120 months after levothyroxine withdrawal (12). The risk of PPT in TPOAb-negative women is approximately one tenth to one hundredth of that in TPOAb-positive women (23). Previous reports have found a relationship between immunogenetic factors such as HLA-DR3, -DR-4 and -DR-5, with thyroid-specific autoimmune diseases (23,24).

Other factors associated with the PPT development are age, multiparty and a previous history of spontaneous abortion (25,26).

**Clinical presentation**

PPT may present as hyperthyroidism, hypothyroidism or may have both clinical presentations (27). The hyperthyroid phase most commonly occurs at 3 months (range between 1 to 6 months) postpartum and lasts only 1–2 months. Postpartum GD usually occurs between 4–7 months postpartum. In the thyrotoxic phase of PPT, the symptoms and signs of hyperthyroidism are milder than during thyrotoxicosis due to GD. The differential diagnosis of these two diseases has been included in the second part of this article.

It has been reported that in 30% of women with PPT, the thyrotoxic phase of the disease is not clinically detected because of lack of symptoms of hyperthyroidism; 20–30% of PPT patients have only hyperthyroid findings and other patients may develop only signs and symptoms of hypothyroidism (approximately 40–50%) (27).

The hypothyroid phase of PPT most commonly occurs at 6 months (range between 3–8 months) postpartum, preceded by a hyperthyroid phase in 25–35% of cases (28,29). The most common presentations of the hypothyroidism phase of PPT are constipation, fatigue, poor memory, loss of concentration and depression (15,23,30). *Figure 1* indicates thyroid status in most common types of PPT.

Postpartum depression (PPD) occurs in 10% of non-selected women (31). The possible relationship between PPD and PPT has long been debated. Hypothyroidism may decrease 5-hydroxytrytamine neurotransmission (32) and cytokines such as IL-1 and IL-6 released during thyroid autoimmune reactions may interact with central neurotransmission and initiate depression (33,34). Some studies have shown the association of thyroid antibodies with PPD whereas others have not (24,35-38).

**Treatment**

In the thyrotoxic phase of PPT, antithyroid drug use is not indicated. Propranolol should be employed for those with fatigue, palpitation, heat intolerance and nervousness. This should be discontinued after 1–2 months, when this phase has subsided.

Levothyroxine should be given in symptomatic women during the hypothyroid phase of PPT (39). Asymptomatic females with TSH levels <10 mU/L who are not planning to get pregnant in the next one year, do not require levothyroxine treatment. They should be re-evaluated in 4-8 weeks. All those with TSH >10 mU/L and subclinical hypothyroid women who are attempting to become pregnant should be treated with levothyroxine.

**Further management**

Postpartum thyroid dysfunction may be transient or permanent (27,39). Majority of women attain euthyroidism within one year after diagnosis. However, abnormalities in thyroid ultrasonography and/or iodine percolate discharge test may persist following recovery from hypothyroidism (40,41). Due to underlying autoimmune thyroid disease, 20–64% of women develop hypothyroidism during follow-up (12,26).

Long-term investigations have been conducted among females with PPT. Reported prevalences of recurrent or permanent hypothyroidism have been 12–23% in 3–3.5 years, 24.5% after 6.6 years and 44% after 8.7 years (11,12,27,41,42). In the largest cohort of PPT patients followed after stopping levothyroxine, hypothyroidism occurred in 63% of 148 women with overt hypothyroidism (12). In the only study that has separated
outcomes in subclinical hypothyroid cases, 53% of women who initially had subclinical hypothyroidism became hypothyroid, for an average of 23 months, following withdrawal of levothyroxine (43). It has been reported that patients with PPTD who remained euthyroid after LT4 withdrawal, had significantly higher TSH levels versus the control group and 73.3% had elevated TPOAb levels (44); hence, if assessed later, many of these patients could be affected by thyroid failure.

**Recommendations**

Both the American Thyroid Association (ATA) and the Endocrine Society have published recommendations (28,29) as follows:

(I) There are insufficient data recommending universal screening for PPT;

(II) Women with positive TPOAb, those with previous history of PPT and females with type 1 diabetes should have a serum TSH measurement 3–6 months after delivery;

(III) Women with PPT who have TSH >10 mU/L and those with subclinical hypothyroidism planning a subsequent pregnancy should be treated with levothyroxine;

(IV) All women with PPT with either overt or subclinical hypothyroidism, treated or untreated with levothyroxine should be followed for several years; even those with euthyroidism without levothyroxine therapy need monitoring for occurrence of hypothyroidism;

(V) Although the association of PPT and PPD is controversial, women with PPD should be screened for hypothyroidism, because hypothyroidism is a potentially reversible cause of depression.

In conclusion, high risk postpartum women should be screened for PPT and individuals with both subclinical and overt PPT should be followed for long durations. Timely diagnosis of the disease and appropriate clinical management and follow-up are vital and improve the quality of life of both mothers and their infants.

**Postpartum thyrotoxicosis**

Hyperthyroidism occurs more frequently during the postpartum period than at any other time in women.
The incidence of postpartum GD is 0.2% (28), whereas that of hyperthyroidism due to postpartum thyroiditis is 10–20 times more than GD in other periods of a woman's life (9,45).

**Pathophysiology**

The immune suppression present during pregnancy is lost after delivery; however, its return to normal following a period of exacerbation of autoimmunity occurs between 3–12 months postpartum and can cause the onset, relapse or exacerbation of autoimmune thyroid diseases (44-46). Therefore, women with a history of GD, in particular those with hyperthyroidism in the first trimester of pregnancy are more likely to have a relapse or exacerbation of symptoms of hyperthyroidism.

In GD, TSH receptor antibodies (TRAb) stimulate thyroid hormone production and secretion by binding to TSH receptors of thyroid cells. Like other autoimmune reactions, the TRAb effect is also suppressed during pregnancy, which explains the improvement or remission of hyperthyroidism in some patients in the third trimester of pregnancy. However, this autoimmune suppression ends a few weeks after delivery when the serum concentration of TRAb may increase, leading to stimulation of thyroid function.

One of the features of this disease is hyperthyroidism which may occur in isolation, or most often prior to a period of hypothyroidism (1). Destruction of thyroid cells by lymphocytes may cause an initial release of thyroid hormones, followed by a transient or permanent fall in hormone synthesis and release (47). Increase in serum thyroid proximate antibodies (TPOAb) is also detectable in GD.

**Clinical presentation**

There might be some difficulty in differentiating symptoms of hyperthyroidism from the normal puerperium experience. Excessive fatigue, feeling sleepiness and manic behavior may be reported by hyperthyroid women during the postpartum period. Fatigue and mood disturbance may simulate a clinical picture of PPD (48). Other symptoms of hyperthyroidism such as irritability and palpitation, heat intolerance, increased sweating and mood swings may be present in some women with postpartum hyperthyroidism, although they overlap with normal postpartum symptoms (49).

In postpartum Graves' hyperthyroid patients, signs such as tachycardia, loss of weight, tremor, thyroid eye disease and diffuse goiter may be present, while in patients in the hyperthyroidism phase of PPT, the symptoms and signs are milder than those of Graves' hyperthyroidism (9,45).

**Laboratory diagnosis**

Combinations of a low or undetectable serum TSH and a high serum free T4 (FT4) or FT4 index and/or T3 confirm the diagnosis of thyrotoxicosis (50). Low serum TSH may be seen in old age, early pregnancy, central hypothyroidism, and postpartum hypophysitis and non-thyroidal illness, none of which may be considered in the clinical setting of these postpartum women. In the postpartum period, thyrotoxicosis may present as subclinical hyperthyroidism with a low or undetectable serum TSH and normal FT4 and free T3 concentrations. Serum FT4 or FT4 index may also be normal in patients with T3 thyrotoxicosis and in those with a low serum thyroxine binding globulin concentration. An elevated FT4 should also be considered in those receiving amiodarone, oral cholecystographic agents, and high doses of propranolol, in amphetamine abuse or in patients with non-thyroidal illnesses and familial dysalbuminemic hyperthyroxinemia (44).

**Causes of postpartum thyrotoxicosis**

Since different etiologies of thyrotoxicosis in the postpartum period necessitate different therapies, it is vital that the diagnosis of the primary cause of the condition be clarified. Essential features of the main etiologies of thyrotoxicosis during the postpartum period are given in Table 1.

**GD**

GD presenting during the first year after delivery is called postpartum GD. The postpartum period is associated with a greater frequency of the onset, exacerbation, and relapse of Graves' hyperthyroidism. The occurrence of postpartum GD has been reported to range between 12% and 40% in women of childbearing age (51). Patients in clinical remission during pregnancy are prone to postpartum relapse. A dramatic rise occurs in serum TRAbs (52) during this period. Clinical symptoms and signs are usually prominent. There are increases in T3, T4 and FT3/FT4 ratio.

**PPT**

Women who develop PPT have mild symptoms of hyperthyroidism or may be asymptomatic. They have
a higher prevalence of positive TPOAb, lesser changes in their T-cell helper/suppressor ratio, and exaggerated thyroid autoantibody responses during pregnancy and postpartum (6). The thyrotoxic phase usually occurs 2–6 months after delivery and is self-limited; women become euthyroid or hypothyroid during the following postpartum months, although GD may coexist with PPT (53).

### Subacute painful thyroiditis
This disorder may rarely occur during the postpartum period and is not related to autoimmune re-activation of this period. The representative clinical features are pain in the region of the thyroid and constitutional symptoms. Serum TSH is usually suppressed and FT4 and free T3 may mildly be increased. Elevated erythrocyte sedimentation rate and a low radioiodine thyroid uptake (RAIU) establish the diagnosis of subacute thyroiditis (54).

### Painless sporadic thyroiditis
Clinical and laboratory characteristics and management of this rare autoimmune disorder are the same as those of the PPT. Patients with painless sporadic thyroiditis have no or very mild symptoms and a small, diffuse goiter is palpable in half of them (54).

### Other forms of thyrotoxicosis
Iatrogenic thyrotoxicosis may very rarely be noted in the differential diagnosis of thyrotoxicosis in a young mother. The diagnosis is confirmed by absence of goiter, a low RAIU and low serum thyroglobulin. Iodine-induced thyrotoxicosis and toxic nodular goiter may also occur in the postpartum period.

### Differential diagnosis
Diagnosis of the etiology of hyperthyroidism may be possible based only on history and physical examination. Findings of thyroid eye disease in GD and a painful thyroid in subacute thyroiditis present the most prominent clinical findings.

The major task is differentiation of GD from the thyrotoxic phase of PPT (55); goiter usually occurs in both diseases but is often more prominent in the former. The RAIU is always low in PPT, elevated or normal in GD; TRAbs are positive in GD and negative in PPT.

Serum triiodothyronine/thyroxine ratio and FT3/FT4 ratio are increased in GD and decreased in most patients with destructive thyroiditis, iatrogenic, or iodine-induced thyrotoxicosis. The RAIU is increased in GD where hyperthyroidism is caused by excessive thyroid hormone synthesis and release; however, various types of thyroiditis

### Table 1 Clinical and laboratory characteristics of main causes of postpartum thyrotoxicosis*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Graves' disease</th>
<th>Postpartum thyroiditis</th>
<th>Painless sporadic thyroiditis</th>
<th>Painful subacute thyroiditis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency</td>
<td>Common</td>
<td>Most common</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td>Timing</td>
<td>4–7 months postpartum</td>
<td>2–6 months postpartum</td>
<td>Any time</td>
<td>Any time (seasonal)</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Hyperthyroidism</td>
<td>Mild hyperthyroidism</td>
<td>None</td>
<td>Fever, malaise</td>
</tr>
<tr>
<td>Signs</td>
<td>Goiter, exophthalmos hyperthyroidism</td>
<td>Goiter</td>
<td>Goiter</td>
<td>Tender goiter, mild hyperthyroidism</td>
</tr>
<tr>
<td>Etiology</td>
<td>Autoimmune</td>
<td>Autoimmune</td>
<td>Autoimmune</td>
<td>Unknown</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>High</td>
</tr>
<tr>
<td>Radiiodine uptake</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Triiodothyronine/thyroxine ratio</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>Variable</td>
</tr>
<tr>
<td>Thyroid peroxidase antibodies</td>
<td>High</td>
<td>High</td>
<td>High</td>
<td>Low or absent</td>
</tr>
<tr>
<td>Thyrotropin receptor-stimulating antibodies</td>
<td>Present</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
</tbody>
</table>

*, rare etiologies are toxic nodular goiter, iodine-induced and iatrogenic thyrotoxicosis.
are accompanied by a low RAIU because inflammatory changes in the thyroid result in suppressed TSH and an inability to iodine concentration (56). Low thyroid RAIU is also detected in exogenous thyroid hormone ingestion, trauma ovarii, and iodine-induced thyrotoxicosis.

In the PPT, increase in serum thyroglobulin concentrations precedes the onset of thyrotoxicosis, while in GD, an elevated thyroglobulin is accompanied by increase in FT4 and free T3 (28). The presence of systematic symptoms, thyroid pain, increased erythrocyte sedimentation rate and C-reactive protein in subacute thyroiditis differentiate this disease from PPT in addition, TPOAb titers are elevated in the latter (57,58). Another discriminating factor is that increased thyroid blood flow in Doppler ultrasonography is seen in GD, while it is low in PPT (59).

**Treatment**

Patients in the thyrotoxic phase of PPT have relatively few symptoms lasting only a few weeks and do not need any treatment. Antithyroid drugs are not indicated because the etiology of hyperthyroidism is excessive release of thyroid hormones and biosynthesis is not increased (60). Sodium ipodate remarkably inhibits the peripheral deiodination of T4 to generate T3 and may be administered 500 mg daily in severe thyrotoxicosis caused by destruction-induced thyrotoxicosis (61).

Radioiodine administration is one therapeutic modality for postpartum GD; however, infant care for up to 7 days or longer according to radiation safety instructions may be very difficult for the mother; likewise, radioiodine treatment is contraindicated in the breast-feeding mother (45).

Antithyroid drugs are the treatment of choice of GD during the postpartum period (46,47). The doses, duration, and follow-up management of hyperthyroidism with antithyroid drugs are the same as those for patients with GD who are not in the postpartum period. Continuing antithyroid drugs for 12–18 months followed by appropriate monitoring to detect any relapse is reasonable and recommended.

If the mother is not breast feeding, radioiodine therapy becomes the treatment of choice when there is contraindication for use of methimazole (MMI) or when side effects are encountered during medical treatment. For the occasional patient who develops side effects of antithyroid drugs and avoids radioiodine treatment, subtotal thyroidectomy would be advisable, following careful control of hyperthyroidism by antithyroid drug (28,29). Subacute painful thyroiditis should be treated with β-blockers. In the presence of moderate or severe signs and symptoms, nonsteroidal anti-inflammatory agents or prednisolone may also be considered.

**Breast-feeding**

Breast-feeding women with hyperthyroidism require special considerations both in diagnosis and management of thyrotoxicosis.

**Diagnosis**

Radioiodine should not be given to breast-feeding women, because it is secreted in the milk. Ingestion of 5–10 µCi doses of 123I and 131I for thyroid uptake test requires discontinuation of nursing for 2 days and few weeks, respectively (62). Use of thyroid RAIU test for the differential diagnosis of thyrotoxicosis must be limited; in special cases, 123I should be used because of its extremely short physical half-life of 13 hours, compared to the 8-day half-life of 131I. In postpartum females who present with clinical and biochemical findings of thyrotoxicosis, if the T3/T4 ratio is >20 and the erythrocyte sedimentation rate is normal, the diagnosis of GD is indicated; confirmation of diagnosis may be made by measurement of TRAb.

**Treatment**

After a long-lasting debate it is now clear that the thyroid function and physical and intellectual development of children, breastfed by thyrotoxic mothers on anti-thyroid drugs remains unaffected (63). It has been shown that treatment of breast-feeding mothers for up to one year (daily dose of 20 and 30 mg MMI) at initiation of treatment and decrease to maintenance dose by the titration method do not cause alterations in the thyroid function of their infants (63-65). Furthermore, thyroid function tests and physical and intellectual growth of these children are all normal and comparable to children who were breastfed by normal non-thyrotoxic mothers (64,66). It is estimated that peak concentration of milk MMI after a dose of 40 mg is 0.72±0.07 µg/mL and that following ingestion of a single 20 mg dose of MMI by mother, the breastfed infant receives approximately 50 µg MMI (7 µg/kg for a 5-month-old infant). Serum MMI concentration of breastfed infants whose mothers received 20–30 mg MMI daily was less than 0.03 µg/mL (44,64). Based on the above
findings, MMI concentration is too low to have any side effects. For more safety, it is recommended to breast-feed the infant before ingestion of MMI (44).

It is concluded that clinicians should carefully proceed with proper diagnosis and treatment of women with postpartum hyperthyroidism and ensure that correct management will improve the quality of life of mothers and their infants.

Acknowledgements

The authors wish to acknowledge Ms. Niloofar Shiva and Dr. Hengameh Abdi for critical editing of English grammar and syntax of the manuscript and Ms. Tahereh Fakhimi for typing the manuscript.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References

25. Azizi F. Age as a predictor of recurrent hypothyroidism


doi: 10.21037/aot.2018.04.04

Cite this article as: Azizi F. Postpartum thyroid disorders. Ann Thyroid 2018;3:13.